Physician profile
David B Wolf
NPI 1447339460
$4,172.97
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $760 · 2021: $1,223 · 2022: $808 · 2023: $564 · 2024: $22.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.35 | 2019-2023 | Tradjenta, Jardiance |
| Lilly USA, LLC | $511.76 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $477.65 | 2019-2022 | |
| Astellas Pharma US INC | $343.41 | 2019-2023 | Veozah |
| Novo Nordisk INC | $327.83 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $323.40 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $240.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $218.51 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $181.50 | 2019-2023 | Eliquis |
| Abbvie INC. | $120.13 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $114.09 | 2019-2021 | |
| Amgen INC. | $84.85 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.82 | 2021-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $67.83 | 2021 | |
| Merck Sharp & Dohme LLC | $59.82 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $41.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $40.31 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.22 | 2022 | |
| Exact Sciences Corporation | $40.05 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $38.74 | 2019-2020 | |
| Circassia INC. | $31.24 | 2019 | |
| Seqirus USA INC | $26.59 | 2019-2022 | |
| Medicomp INC | $22.00 | 2022 | |
| Embecta Corp. | $21.63 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $19.71 | 2022 | |
| Corium, LLC | $19.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2020 | |
| Bardy Diagnostics, INC. | $15.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.